← Leaderboards
Ilyas Washington
Alkeus Pharmaceuticals, Inc.
$6,048,568
Attributed
$8,286,786
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2011–23$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,120,802 · 5
FDA$2,165,984 · 2
By mechanism
R01$4,087,359 · 3
R44$3,810,330 · 2
R43$223,898 · 1
R41$165,199 · 1
Top collaborators
- Leonide Saad8 shared
- Doina Mihai1 shared
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventSmall MoleculePharmaceutical PreparationsAnimalsAffectAnimal ModelSymptomsDeuteriumBlindnessLeadHydrogenElderlyMacular DegenerationDimerVisionVitamin ARetinal DegenerationSafetyTissuesImpairmentClinical TrialsPublic HealthDesignOral
Grant awards (18)
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2023 · FD
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2021 · FD
A diabetes pill to replace insulin injections$759,882
R44 · FY2020 · DK · contact PI
A diabetes pill to replace insulin injections$740,045
R44 · FY2019 · DK · contact PI
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2019 · FD
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$250,000
R01 · FY2018 · FD
A diabetes pill to replace insulin injections$223,848
R44 · FY2018 · DK · contact PI
A Phase 2a clinical trial of ALK-001 in geographic atrophy$1,032,268
R44 · FY2017 · EY
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$249,112
R01 · FY2017 · FD
Evaluation of a therapeutic strategy to combat osteoarthritis$223,898
R43 · FY2017 · AG
A Phase 2a clinical trial of ALK-001 in geographic atrophy$1,054,287
R44 · FY2016 · EY
The role and mechanisms of lipofuscin formation in macular degeneration$394,450
R01 · FY2015 · EY · contact PI
The role and mechanisms of lipofuscin formation in macular degeneration$394,450
R01 · FY2014 · EY · contact PI
The role and mechanisms of lipofuscin formation in macular degeneration$382,375
R01 · FY2013 · EY · contact PI
Phase 1 Study of ALK001 for Stargardt Disease$166,872
R01 · FY2013 · FD
The role and mechanisms of lipofuscin formation in macular degeneration$402,500
R01 · FY2012 · EY · contact PI
Phase 1 Safety and Pharmacokinetics of ALK001 in people over 60$165,199
R41 · FY2012 · EY · contact PI
The role and mechanisms of lipofuscin formation in macular degeneration$347,600
R01 · FY2011 · EY · contact PI